Comparative Pharmacology
Head-to-head clinical analysis: CARBIDOPA LEVODOPA AND ENTACAPONE versus DOPAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARBIDOPA LEVODOPA AND ENTACAPONE versus DOPAR.
CARBIDOPA, LEVODOPA AND ENTACAPONE vs DOPAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levodopa is a precursor to dopamine that crosses the blood-brain barrier and is converted to dopamine by aromatic L-amino acid decarboxylase, replenishing depleted dopamine in the striatum. Carbidopa inhibits peripheral decarboxylation of levodopa, increasing its availability to the brain and reducing peripheral side effects. Entacapone is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT), primarily in the periphery, which prolongs the half-life and duration of action of levodopa by reducing its conversion to 3-O-methyldopa.
DOPAR (levodopa) is a metabolic precursor of dopamine. It crosses the blood-brain barrier and is converted to dopamine by aromatic L-amino acid decarboxylase (AADC) in the brain, thereby replenishing striatal dopamine levels and alleviating symptoms of Parkinson's disease.
One tablet (carbidopa 25 mg/levodopa 100 mg/entacapone 200 mg) orally up to a maximum of 8 tablets per day in divided doses. Optimal dose individualized based on response and tolerance.
Levodopa 300-600 mg orally 3-4 times daily as Dopar; do not crush or chew extended-release.
None Documented
None Documented
Levodopa: 1-2 hours (short half-life necessitates frequent dosing with carbidopa to inhibit peripheral decarboxylation). Carbidopa: 2-3 hours. Entacapone: 1-2 hours (terminal half-life prolonged with levodopa). Clinical context: entacapone prolongs levodopa's half-life by inhibiting COMT.
Terminal half-life: 1-3 hours (levodopa alone); with carbidopa (Sinemet): 1.5-2 hours due to reduced peripheral metabolism; clinical context: short half-life requires frequent dosing (every 4-6 hours) to maintain therapeutic levels.
Levodopa: renal excretion of metabolites (dopamine, DOPAC, HVA) and unchanged drug (<1%); carbidopa: 70% renal as unchanged drug and metabolites; entacapone: 90% fecal (biliary), 10% renal.
Renal: 70-80% as metabolites (including homovanillic acid, dihydroxyphenylacetic acid, and 3-O-methyldopa); biliary/fecal: ~20% as conjugates and metabolites; unchanged levodopa <1%.
Category A/B
Category C
Dopamine Precursor
Dopamine Precursor